While patients who undergo percutaneous closure of ventricular septal defect (VSD) have a high rate of in-hospital mortality, long-term outcomes are generally favorable in those who survive to ...
Percutaneous closure of symptomatic ventricular septal defects in children can be achieved with off-label use of an occluder device. A research letter published online November 7, 2012, ahead of print ...
Muscular ventricular septal defects (mVSD) appearing together with other septal defects are frequently regarded as ‘concomitant’ pathologies, that nevertheless should be considered while the patient ...
After bicuspid aortic valve, ventricular septal defects (VSDs) are the most common congenital heart abnormalities. Of all congenital defects, around 20% are solitary lesions and another 10% are ...
Based on a few hundred cases, 5-year all-cause mortality was approximately 60% between patients assigned an initial management strategy of surgery and those undergoing percutaneous treatment (log-rank ...
Percutaneous closure can be described as a less-invasive surgical procedure used to treat patients with atrial septal defect (ASD) or patent foramen ovale (PFO). Since the utilization of percutaneous ...
MINNEAPOLIS, Sept. 10 AGA Medical Corporation ("AGA")announced today that it has received U.S. Food and Drug Administration (FDA)approval to market the AMPLATZER Muscular Ventricular Septal (VSD) ...
A ventricular septal defect (VSD) occurs when there is direct communication between the left and right ventricles. This can be a congenital anomaly or acquired as a complication of a myocardial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback